Shanghai Junshi Biosciences Co., Ltd. Class H ( (HK:1877) ) has provided an announcement.
Shanghai Junshi Biosciences Co., Ltd. has received approval from the National Medical Products Administration to conduct clinical trials for its JS212 injection, a bispecific antibody-drug conjugate targeting EGFR and HER3. This approval marks a significant step in the company’s efforts to develop treatments for advanced solid tumors, potentially enhancing its market position in oncology by addressing drug resistance and offering broader therapeutic applications.
More about Shanghai Junshi Biosciences Co., Ltd. Class H
Shanghai Junshi Biosciences Co., Ltd. is a pharmaceutical company based in China, focusing on the development of innovative drugs, particularly in the field of oncology. The company specializes in creating antibody-drug conjugates (ADCs) for the treatment of various cancers, aiming to address drug resistance and improve treatment efficacy.
YTD Price Performance: 31.61%
Average Trading Volume: 1,527,996
Technical Sentiment Consensus Rating: Sell
Current Market Cap: HK$28.14B
For an in-depth examination of 1877 stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
Questions or Comments about the article? Write to editor@tipranks.com